← Back to Clinical Trials
Recruiting NCT06748976

NCT06748976 Modulation of Cortical Brain Activity During Attentional Control

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06748976
Status Recruiting
Phase
Sponsor National Council of Scientific and Technical Research, Argentina
Condition Rumination
Study Type OBSERVATIONAL
Enrollment 35 participants
Start Date 2025-07-01
Primary Completion 2025-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type OBSERVATIONAL
Interventions
Positive sham neurofeedbackNegative sham neurofeedbackControl

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 35 participants in total. It began in 2025-07-01 with a primary completion date of 2025-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to determine whether an open-loop sham neurofeedback system can effectively modulate EEG alpha rhythms, which are associated with attentional control. The main questions it aims to answer are: Does positive sham neurofeedback lead to a decrease in relative EEG alpha power compared to a control condition without feedback? Researchers will compare the effects of positive and negative sham-neurofeedback conditions to a control condition without feedback to assess the system's impact on alpha rhythm modulation. Participants will: Experience three conditions (positive sham-neurofeedback, negative sham-neurofeedback, and no feedback) within a virtual reality environment. Undergo EEG recordings to measure changes in alpha power as a marker of attentional resource allocation. Provide written informed consent and complete the study following ethical guidelines. This study seeks to explore the potential of open-loop feedback systems to enhance attentional control by modulating alpha rhythm.

Eligibility Criteria

Inclusion Criteria: * Adults aged between 18 and 60 years. * Normal or corrected vision. * Ability to provide written informed consent. Exclusion Criteria: * Diagnosed with photosensitive epilepsy. * Significant hearing loss or diagnosed hearing impairment. * Current psychiatric illness or disorder. * History of migraines or chronic headaches. * History of substance or alcohol abuse. * Currently pregnant. * Discomfort with using a virtual reality headset, assessed during a pilot session.

Contact & Investigator

Central Contact

José Alberto Biurrun Manresa, PhD

✉ jose.biurrun@uner.edu.ar

📞 +543434975100120

Frequently Asked Questions

Who can join the NCT06748976 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Rumination. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06748976 currently recruiting?

Yes, NCT06748976 is actively recruiting participants. Contact the research team at jose.biurrun@uner.edu.ar for enrollment information.

Where is the NCT06748976 trial being conducted?

This trial is being conducted at Oro Verde, Argentina.

Who is sponsoring the NCT06748976 clinical trial?

NCT06748976 is sponsored by National Council of Scientific and Technical Research, Argentina. The trial plans to enroll 35 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology